POST Online Media Lite Edition



 

Swiss Competition Commission COMCO investigation against pharma suppliers ongoing

Christian Fernsby |
The Swiss Competition Commission (COMCO) has opened an investigation against several manufacturers and distributors of active pharmaceutical ingredients.

Article continues below



Topics: SWISS    COMPETITION    COMMISSION    COMCO    INVESTIGATION    PHARMA   

COMCO has conducted several dawn raids.

COMCO suspects that manufacturers and distributers of the active pharmaceutical ingredient Scopolamine Butylbromide have concluded unlawful price and market sharing agreements.

There are reasonable grounds to suspect that the undertakings have kept the prices of this pharmaceutical ingredient high and that they have allocated markets.

The investigation shall examine whether there are indeed unlawful restrictions of competition.

This pharmaceutical ingredient is used for the production of drugs against spasmodic stomach pains, renal colic and bladder spasms.

The manufacturers and distributors of Scopolamine Butylbromide resell this pharmaceutical ingredient to drug manufacturers.


What to read next

Highlights: September 12 - September 16, 2016
Highlights: September 18 - September 21, 2017
Swiss watch exports experience first downturn in seven years